Apalutamide is a competitive inhibitor of the androgen receptor and binds directly to the ligand-binding domain. The US Food and Drug Administration approved apalutamide on 14 February 2018 for use in patients with nonmetastatic castration-resistant prostate cancer based upon results from the phase III SPARTAN trial demonstrating significantly longer metastasis-free survival over placebo. The SPARTAN trial evaluated 1207 patients with nonmetastatic castration-resistant prostate cancer who were randomized 2:1 to apalutamide or placebo in combination with androgen deprivation therapy. Patients who received apalutamide experienced statistically significantly longer metastasis-free survival (40.5 versus 16.2 months, hazard ratio 0.28 (95% confidence interval = 0.23–0.35); P < 0.0001), which was the major efficacy outcome. Rash, hypothyroidism, and fracture were reported to occur more frequently with apalutamide than placebo. Based upon these results, apalutamide was deemed a safe and effective treatment option for patients with nonmetastatic castration-resistant prostate cancer. Clinical trials are ongoing to expand its indication in the metastatic setting, and identify additional roles for apalutamide in the management of prostate cancer such as in the castrate-sensitive metastatic setting.
American Cancer Society. Cancer facts & figures 2019. Atlanta, GA: American Cancer Society, 2019.
2.
National Comprehensive Cancer Network (NCCN) Clinical practice guidelines in oncology (NCCN Guidelines). Prostate cancer. Version 2.2019, http://www.nccn.org (2019, accessed 10 June 2019).
3.
Hahn AW, Higano CS, Taplin ME, et al. Metastatic castration-sensitive prostate cancer: optimizing patient selection and treatment. ASCO Educational Book, www.asco.org/edbook (2018, accessed 19 June 2019).
4.
HussainMFizaziKSaadF, et al.Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer. N Engl J Med2018; 378: 2465–2474.
5.
SmithMRSaadFChowdhuryS, et al.Apalutamide treatment and metastasis-free survival in prostate cancer. N Engl J Med2018; 378: 1408–1418.
6.
ChongJTOhWKLiawBC. Profile of apalutamide in the treatment of metastatic castration-resistant prostate cancer: evidence to date. Onco Targets Ther2018; 11: 2141–2147.
7.
CleggNJWongvipatJJosephJD, et al.ARN-509: a novel antiandrogen for prostate cancer treatment. Cancer Res2012; 72: 1494–1503.
RathkopfDEMorrisMJFoxJJ, et al.Phase I study of ARN-509, a novel antiandrogen, in the treatment of castration-resistant prostate cancer. J Clin Oncol2013; 31: 3525–3530.
10.
BeaverJAKluetzPGPazdurR. Metastasis-free survival – a new end point in prostate cancer trials. N Engl J Med2018; 378: 2458–2460.
SmallEJLeeJYLopez-GitlitzA, et al.Prostate-specific antigen (PSA) outcomes in patients (PTS) with nonmetastatic castration-resistant prostate cancer (NMCRPC) treated with apalutamide (APA): results from phase 3 Spartan study. J Urol2019; 199. : abstr PD10-11.
13.
GraffJNSaadFHadschikBA, et al.Metastasis-free survival (MFS) in nonmetastatic castration-resistant prostate cancer (NMCRPC) patients (PTS) with prostate-specific antigen (PSA) decline to <0.2 ng/mL following apalutamide (APA) treatment: post hoc results from the phase 3 Spartan study. J Urol2019; 201: abstr MP34–20.
14.
HadaschikBASaadFGraffJN, et al.Efficacy and safety of apalutamide (APA) in nonmetastatic castration-resistant prostate cancer (NMCRPC) patients (PTS) with or without prior radical prostatectomy (RP) and/or external radiotherapy (XRT): post hoc analysis of Spartan. J Urol2019; 201: abstr MP34–19.
15.
GraffJNSmithMRSaadF, et al.Age-related efficacy and safety of apalutamide (APA) plus ongoing androgen deprivation therapy (ADT) in subgroups of patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC): post hoc analysis of SPARTAN. J Clin Oncol2019; 37: abstr 5024.
16.
SmallEJSaadFChowdhuryS, et al.Efficacy of apalutamide (APA) plus ongoing androgen deprivation therapy (ADT) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) and baseline (BL) comorbidities (CM). J Clin Oncol2019; 37: abstr 5023.
17.
ChiKNAgarwalNBjartellA, et al.Apalutamide for metastatic, castration-sensitive prostate cancer. N Engl J Med.. 2019; 381: 13–24. DOI: 10.1056/NEJMoa1903307.
18.
CosmanFde BeurSJLeBoffMS, et al.Clinician's guide to prevention and treatment of osteoporosis. Osteoporosis Int2014; 25: 2359–2381.
19.
PollockYYGSmithMRSaadF, et al.Predictors of falls and fractures in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) treated with apalutamide (APA) plus ongoing androgen deprivation therapy (ADT). J Clin Oncol2019; 37. : abstr 5025.
20.
Supplementary Appendix to ChiKNAgarwalNBjartellA, et al.Apalutamide for metastatic, castration-sensitive prostate cancer. N Engl J Med.. Epub ahead of print 31 May 2019. DOI: 10.1056/NEJMoa1903307 (31 May 2019).
21.
BelderbosBSWitRChienC, et al.An open-label, multicenter, phase Ib study investigating the effect of apalutamide on ventricular repolarization in men with castration-resistant prostate cancer. Cancer Chemother Pharmacol2018; 82: 457–468.
RyanCJCrawfordEDShoreND, et al.The IMAAGEN study: effect of abiraterone acetate and prednisone on prostate specific antigen and radiographic disease progression in patients with nonmetastatic castration resistant prostate cancer. J Urol2018; 200: 344–352.
24.
SmithMRAnonarakisESRyanCJ, et al.Phase 2 study of the safety and antitumor activity of apalutamide (ARN-509), a potent androgen receptor antagonist, in the high-risk nonmetastatic castration-resistant prostate cancer cohort. Eur Urol2016; 70: 963–970.
25.
SaadFCellaDBaschE, et al.Effect of apalutamide on health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the SPARTAN randomized, placebo-controlled, phase 3 trial. Lancet Oncol2018; 19: 1404–1416.
26.
Nieto-GomezPUbago-PerezRCabeza-BarreraJ. Efficacy of enzalutamide and apalutamide in treatment of non-metastatic castration-resistant prostate cancer: indirect comparison. Actas Urol Esp.. Epub ahead of print 24 May 2019. DOI: 10.1016/j.acuro.2019.03.007.
27.
WallisCJDChandrasekarTGoldbergH, et al.Advanced androgen blockage in nonmetastatic castration-resistant prostate cancer: an indirect comparison of apalutamide and enzalutamide. Eur Urol Oncol2018; 1: 238–241.
28.
SchultzNMSugarmanRRamaswamyK, et al.Clinical benefits and risks of enzalutamide and apalutamide: number needed to treat and number needed to harm analysis for patients with non-metastatic castration resistant prostate cancer. J Urol2019; 201: abstr MP34–18.
RathkopfDEAntonarakisESShoreND, et al.Safety and antitumor activity of apalutamide (ARN-509) in metastatic castration-resistant prostate cancer with and without prior abiraterone acetate and prednisone. Clin Cancer Res2017; 23: 3544–3551.
31.
U.S. National Library of Medicine. ClinicalTrails.gov, 2019, https://clinicaltrials.gov/ (accessed 10 June 2019).
32.
ClinicalTrials.gov. Identifier NCT03080116. Neoadjuvant degarelix ± apalutamide (ARN-509) followed by radical prostatectomy (ARNEO). Bethesda, MD: National Library of Medicine (US), https://clinicaltrials.gov/ct2/show/NCT03080116 (accessed 10 June 2019).
33.
ClinicalTrials.gov. Identifier NCT02257736. An efficacy and safety study of apalutamide in combination with abiraterone acetate and prednisone versus abiraterone acetate and prednisone in participants with chemotherapy-naïve metastatic castration-resistant prostate cancer. Bethesda, MD: National Library of Medicine (US), https://clinicaltrials.gov/ct2/show/NCT02257736 (accessed 10 June 2019).
34.
SandlerHMMcKenzieMRTombalBF, et al.ATLAS: a randomized #double-blind, placebo-controlled, phase III trial of apalutamide (ARN-509) in patients with high-risk localized or locally advanced prostate cancer receiving primary radiation therapy. J Clin Oncol2017; 34: 15_Suppl.
35.
WerutskyG, et al.The LACOG-0415 phase II trial: abiraterone acetate and ADT versus apalutamide versus abiraterone acetate and apalutamide in patients with advanced prostate cancer with non-castration testosterone levels. BMC Cancer2019; 19: 487.
36.
ClinicalTrials.gov. Identifier NCT02867020. Study of abiraterone acetate plus ADT versus apalutamide versus abiraterone and apalutamide in patients with advanced prostate cancer with non-castrate testosterone levels. Bethesda, MD: National Library of Medicine (US), https://clinicaltrials.gov/ct2/show/NCT02867020 (accessed 10 June 2019).
